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Summary The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-
line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease
entered this trial, of whom 232 patients were eligible. Treatment consisted of doxorubicin 75 mg m-2 or epirubicin 90 mg m-2 i.v. every 3
weeks. The overall response rates for doxorubicin and epirubicin were 36% and 28% respectively (P = 0.173). The median time to
progression was 23 weeks for doxorubicin and 19 weeks for epirubicin (P = 0.063) and the median duration of response was 40 weeks for
doxorubicin and 32 weeks for epirubicin (P = 0.059). The median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (P =
0.196). Leucocyte count on retreatment day (P = 0.011) and platelet nadir (P = 0.031) were significantly lower in the doxorubicin-treated
group. Also mucositis (P < 0.001), diarrhoea (P = 0.005) and haemorrhage (P = 0.048) were significantly worse in the doxorubicin arm. Nine
patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no
statistical differences in response rate and survival were found between the two treatment arms. Treatment with doxorubicin tended to result
in a slightly longer duration of response and time to progression but doxorubicin was more toxic than epirubicin.
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Doxorubicin is among the most effective chemotherapeutic drugs
in the treatment ofmetastatic breast cancer. Used as a single agent,
doxorubicin induces response rates ofapproximately 40% as first-
line chemotherapy and about 20% as second-line therapy after
failure or relapse on combination chemotherapy (Tormey et al,
1975; Hoogstraten et al, 1976).
Although the acute toxicities of doxorubicin are manageable,
the major cumulative dose-limiting toxic effect of the drug is the
development ofcongestive heart failure (CHF), which may be irre-
versible and lethal (Lefrak et al, 1975; Von Hoff et al, 1979). The
risk of CHF induction with doxorubicin is limited at a cumulative
dose of less than 550 mg m-2, but increases rapidly thereafter,
preventing the continuation of the use of the drug beyond this
dose. Since the early 1970s, there has been a continuous search for
anthracycline analogues with a more favourable therapeutic
profile than doxorubicin. A number ofanthracycline derivatives of
lower cardiotoxic potential in animal models have been introduced
into clinical trials, of which one is epirubicin, an analogue
resulting from the epimerization of 4'-hydroxyl of doxorubicin
(Rozencweig et al, 1979). The mechanism of action of epirubicin
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is similar to that of doxorubicin: binding to DNA and inhibiting
synthesis and function of nucleic acid (Young and Weenen, 1984).
Experimental and phase I studies in breast cancer suggested that
epirubicin had a more favourable therapeutic index than doxoru-
bicin, i.e. similar anti-tumour activity but less toxicity (Casazza et
al, 1980; Schrauer et al, 1981; Bonfante et al, 1982; Young and
Weenen, 1984). In the early phase II studies in metastatic breast
cancer, epirubicin showed anti-tumour activity similar to that of
doxorubicin (Rozencweig et al, 1984). The toxicities encountered
with epirubicin therapy were: leucopenia, nausea and vomiting
and no severe life-threatening cardiac toxicity up to a cumulative
dose ofabout 1000 mg m-2.
In view of these early data, the EORTC Breast Cancer
Cooperative Group decided to conduct a randomized phase I1III1
study directly comparing epirubicin with doxorubicin. The objec-
tives of the study were to assess the objective anti-tumour activity
and the toxic effects of epirubicin, and to evaluate the cross-resis-
tance between the anthracycline analogues. Both drugs were given
as single agents in patients with metastatic breast cancer relapsing
after previous chemotherapy without anthracyclines. The dose
levels selected for epirubicin and doxorubicin were 90 mg m-2 and
75 mg m-2 respectively. Both drugs were administered as an i.v.
bolus injection every 3 weeks. Based on the limited data, available
at that time, of previous investigations, epirubicin 90 mg m-2 was
anticipated to induce degrees of myelosuppression equivalent to
doxorubicin 75 mg m-2 (Rozencweig et al, 1984; Bonfante et al,
1982). Haematological growth factors were not used in this study.
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MATERIALS AND METHODS
Patients with metastatic breast cancer were eligible for this study,
after giving informed consent according to the rules of the parti-
cipating institution.
Measurable or evaluable progressive disease was required as
well as a performance status (WHO) better than 3. Patients with
liver enlargement, pleural effusion, ascites, bone marrow involve-
ment or osteoblastic lesions were not considered to be evaluable.
In addition, patients were excluded ifthey had received more than
one previous combination chemotherapy regimen without anthra-
cyclines, as adjuvant therapy or for metastatic disease. Other
exclusion criteria included renal (creatinine > 1.2 mg dl-') and/or
hepatic (bilirubin > 1.5 mg dl-') dysfunction, congestive heart
failure, significant arrhythmia, bilateral bundle branch block or
history of myocardial infarction as well as previous or concurrent
malignancies (except adequately treated carcinoma in situ of the
cervix and/or carcinoma ofthe skin).
Study design
Eligible patients were randomized between epirubicin and doxoru-
bicin treatment by telephoning the EORTC data centre. Patients
were stratified by institution. Patients failing either epirubicin or
doxorubicin, after two, three or four courses, were to be crossed
over to doxorubicin or epirubicin respectively. Originally the study
was started as a randomized phase II trial, but after an interim
analysis had been performed, it was continued as a phase III trial.
Treatment protocol
The doses of epirubicin and of doxorubicin were 90 mg m-2 and
75 mg m-2 respectively. Both drugs were administered as an i.v.
bolus injection and cycles were repeated every 3 weeks.
Dose modifications
Treatment was delayed by 1 week if WBC was < 3 x 109 1-' or
platelets < 100 x 109 1-' at the scheduled time of the subsequent
cycle. Further dose adjustments were made as follows: 50% of the
dose if after a I-week delay the WBC count was between 2 and
2.9 x 109 1-' and/or platelets between 50 and 99 x 1091-1; or post-
ponement for another week if the WBC count was < 2 x 109 1-' or
platelets < 50 x 109 1-'. If postponement was required for more
than 3 weeks the patient went offstudy. The dose was also reduced
to 50% ifbilirubin level ranged between 2 and 3 mg dl-' and to 0%
with a bilirubin level above 3 mg dl-'. Other reasons for with-
drawal from treatment were patients refusal or persistent severe
side-effects other than haematological toxicity, congestive heart
failure and neutropenic sepsis.
Treatment duration
Patients with remission or stable disease after two courses
continued treatment until the disease progressed. On disease
progression, patients on epirubicin or on doxorubicin having
received less than five courses were crossed over to doxorubicin or
epirubicin respectively. Treatment was stopped at a cumulative
dose of 550 mg m-2 for doxorubicin and, initially, also for epiru-
bicin. After 100 patients had been entered, the maximum epiru-
bicin cumulative dose was increased to 900 mg m-2.
Table 1 Patient characteristics at entry (all eligible patients)
Doxorubicin (n = 118) Epirubicin (n = 114)
Median age (range) (years) 56 (31-75) 56 (34-73)
Performance status WHO (n)
0 38 (32)a 35 (31)
1 49 (42) 53 (46)
2 28 (24) 25 (22)
Unknown 3 (2) 1 (1)
Prior endocrine therapy
None 31 (26) 33 (29)
Ablative 22 (19) 19 (17)
Additive 43 (36) 48 (42)
Both 13 (11) 10 (9)
Unknown 9 (8) 4 (4)
Prior chemotherapy 115 (98) 110 (97)
Dominant site
Soft tissue 37 (31) 27 (24)
Bone 32 (27) 31 (27)
Visceral 49(42) 56 (49)
Menopausal status
Before menopause 0 (0) 4 (4)
Natural menopause 71 (60) 80 (70)
Artificial menopause 38 (32) 25 (22)
Unknown 9 (8) 5 (4)
aNumbers in parentheses are percentages.
Table 2 Treatment duration and dosages (all eligible patients who started
the treatment)
Doxorubicin (n = 116) Epirubicin (n = 113)
Duration of treatment (days)
Median (range) 127 (1-314) 113 (1-323)
No. with information 116 113
Dosage
Total dose (mg)
Median (range) 568 (80-1476) 800 (140-2250)
No. with information 101 97
Total dose (mg m-2)
Median (range) 383 (47-911) 447 (88-1452)
No. with information 92 93
Total dose (mg m-2) week-1)
Median (range) 23 (10-38) 27 (12-49)
No. with information 90 92
Total dose as a percentage of
the planned dose
Median (range) 90 (41-154) 91(40-162)
No. with information 90 92
Relative dose intensity (n)
< 70% 14 (16)a 13 (14)
70-89% 30 (33) 31 (34)
90-109% 32 (36) 35 (38)
>110% 14 (16) 13 (14)
No. with information 90 92
Reductions
No 52 (58) 64 (70)
At least once 38 (42) 28 (30)
Delay
No 42 (47) 51 (55)
At least once 48 (53) 41 (45)
aNumbers in parentheses are percentages.
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Table 3 Response rate (all eligible patients)
Doxorubicin Epirubicin
(n=118) (n=114)
n % n %
Complete response 5 4 2 2
Partial response 38 32 30 26
No change 37 31 45 40
Progression/early death/not evaluable 38 32 37 33
Progression 18 15 23 20
Early death due to malignant disease 1 1 0 0
Early death due to toxicity 3 2 0 0
Not evaluable 16 14 14 13
Two-sided P-value for trend 0.324
Percentage of responders
CR or PR 43 36 32 28
No objective response 75 64 82 72
Two-sided P-value for comparison 0.173
of the percentage of response
Pretreatment and follow-up studies
Baseline investigations included history and physical examination,
performance status, tumour measurements, complete blood count,
chemistries, chest radiography, a bone scan or skeletal survey,
electrocardiogram (ECG) and, preferentially, measurement of the
isotopic left ventricular ejection fraction (LVEF). All baseline
investigations were repeated after two courses and thereafter every
3-6 weeks. Chest radiography, bone scan and/or bone surveys
were repeated every 12 weeks. WBC and platelet nadirs were
measured weekly during the first two treatment cycles.
Evaluation of response and toxicity
Patients were evaluable for response if they had received at least
two courses of chemotherapy and if tumour measurements had
been repeated at 6 weeks. Assessment of response was performed
according to the UICC criteria (Hayward et al, 1977). Toxicity was
assessed according to the WHO criteria (WHO, 1979). Duration of
complete or partial response was measured from the date of
randomization until the date ofprogressive disease. All cases were
subjected to extramural review performed by both the study coor-
dinator (AT van Oosterom) and an external reviewer with respect
to eligibility and evaluability, treatment effectiveness, toxicity, the
correct reporting of the data described in the files and their repre-
sentation on the forms.
Statistics
Assuming a response rate for doxorubicin of 30%, and to have a
power of 0.85 to detect a difference of 20% for epirubicin, a
sample size of 116 evaluable patients for each arm was required
(ox = 0.05, p = 0.15, two-sided test).
The response to treatment and the degree of toxicity were
compared using the chi-square test for proportions and the chi-
square test for linear trend. Leucocyte and platelet values were
compared using the Wilcoxon rank-sum test. Progression and
survival curves were calculated based on the Kaplan-Meier
product-limit estimate and compared using the log-rank test.
Adjustment for imbalances in prognostic factors was carried out
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by means ofretrospective stratification. Except for patients lost to
follow-up, all patients were followed until death.
RESULTS
Patient characteristics
Within this study (EORTC 10811) 259 patients were randomized
by ten institutions between June 1982 and May 1986 - 128
patients to doxorubicin and 131 to epirubicin. Twenty-seven
patients (ten on doxorubicin, 17 on epirubicin) were ineligible.
Reasons for ineligibility were: prior orconcomittant treatment (n =
4), poor performance status (n = 7), insufficient WBC count (n =
3), cardiovascular disease (n = 4), non-measurable disease (n = 4),
brain metastases (n = 2), insufficient data (n = 2) and previous
endometrial cancer (n = 1).
The characteristics ofthe 232 eligible patients are given in Table
1. The two treatment groups were well balanced with respect to
age, performance status and prior hormono- or chemotherapy. For
the dominant site, a small imbalance was observed: visceral
lesions were more frequent in the epirubicin arm and there were
more soft tissue lesions in the doxorubicin arm. Previous adjuvant
therapy was not recorded on the forms, but prior chemotherapy
had mainly been applied for advanced disease.
Treatment duration and dosages
Three eligible patients never started their treatment. One patient in
the doxorubicin arm had an episode of infection soon after
randomization, and another one refused to start the treatment. One
patient in the epirubicin arm died suddenly before the treatment
was started.
The median number oftreatment courses was five in both arms:
range one to 14 cycles in the doxorubicin arm and one to 15 cycles
in the epirubicin arm. Treatment duration and total dosages admin-
istered are given in Table 2. The median duration oftreatment was
127 days in the doxorubicin arm (range 1-314 days) and 113 days
in the epirubicin arm (range 1-323 days). The median dose ofdrug
received per m2 was 383 mg in the doxorubicin arm (range 47-
911 mg) and 447 mg in the epirubicin arm (range 88-1452 mg).
The median dose intensity was 90% in the doxorubicin arm (range
41-154%) and 91% in the epirubicin arm (range 40-162%). Fifty-
three per cent of the patients in the doxorubicin arm and 45% of
the patients in the epirubicin arm had at least one cycle delayed.
Dose reductions occurred in 42% and 30% of the patients in the
doxorubicin and epirubicin arms respectively. Twenty-one patients
on doxorubicin and 16 on epirubicin stopped the treatment prema-
turely because of toxicity or treatment refusal. Eleven patients on
epirubicin stopped the treatment while still responding at a median
cumulative dose of544 mg m-2 (range 495-1452 mg m-2, i.e. . six
cycles).
Treatment efficacy
Including the non-evaluable patients, the response rate (CR + PR)
was 36% for the doxorubicin arm (95% Cl 28-45%) and 28% for
the epirubicin arm (95% CI 20-36%, Table 3). This difference of
8% in the response rate (95% CI -3% to +20%) is not significant
using the chi-square test (P = 0.173). Likewise, it is not significant
using a test for linear trend (P = 0.324 for CR vs PR vs NC vs
other). When stratified by the dominant site of the disease, there
Table 4 Haematological toxicity (all eligible patients who started the
treatment)
Doxorubicin Epirubicin PLvaluea
(n = 116) (n = 113)
Leukocytes (109 Fl)
Nadir over the whole
treatment period
Median (range) 2.5 (0.2-3.9) 2.8 (0.2-4.0)
No. with information 60 56 0.150
Worst retreatment value
over the whole treatment
Median (range) 3.6 (2.0-10.3) 3.9 (2.3-12.7)
No. with information 103 107 0.011
Nadir over the first two cycles
Median (range) 2.5 (0.2-3.9) 2.7 (0.2-4.0)
No. with information 42 38 0.429
Worst retreatment value
over the first two cycles
Median (range) 4.0 (2.2-10.5) 4.3 (2.5-17.5)
No. with information 103 107 0.030
Platelets (109 Fl)
Nadir over the whole
treatment period
Median (range) 88 (8-206) 143 (27-335)
No. with information 24 22 0.031
Worst retreatment value
over the whole treatment
Median (range) 244 (50-592) 266 (105-552)
No. with information 102 107 0.077
Nadir over the first two cycles
Median (range) 77 (8-301) 127 (27-335)
No. with information 19 17 0.163
Worst retreatment value
over the first two cycles
Median (range) 290 (50-656) 279 (107-692)
No. with information 102 107 0.778
aWilcoxon rank-sum test.
was no significant difference in response between both drugs (P =
0.436). The duration of response among the complete (CR) and
partial (PR) responders is presented in Figure 1. The median dura-
tion ofresponse, as measured from the date ofrandomization, was
40 weeks for doxorubicin and 32 weeks for epirubicin. Using the
log-rank test, this difference approaches significance (P = 0.059).
Time to progression for all eligible patients is presented in
Figure 2. The median time to progression was 23 weeks for
doxorubicin and 19 weeks for epirubicin. Using the log-rank test
with or without adjustment for dominant site, this difference is not
statistically significant (unstratified P = 0.063, stratified P =
0.085). Figure 3 shows the duration of overall survival for all
eligible patients. The median survival for patients treated with
doxorubicin was 47 weeks and for patients treated with epirubicin
44 weeks (unstratified P = 0.196, stratified P = 0.385). An analysis
of time to progression and duration of survival in all randomized
patients yielded similar results. A total of five patients initially
treated with epirubicin were crossed over to doxorubicin treatment
because ofprogressive disease. None of these patients responded.
Among nine patients not responding to first-line doxorubicin, one
PR (11%) was observed with the use of second-line epirubicin
treatment.
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Table 5 Non-haematological toxicity (worst grade reported during the
treatment period for all eligible patients who started the treatment)
Grade Total P-value
0 1 2 3 4
Oral
Doxorubicin 57 26 24 7 0 114
Epirubicin 89 13 10 1 0 113 <0.001
Diarrhoea
Doxorubicin 88 11 12 2 1 114 0.005
Epirubicin 103 4 6 0 0 113
Haemorrhage
Doxorubicin 104 5 4 1 0 114
Epirubicin 111 0 2 0 0 113 0.048
Nausea/vomiting
Doxorubicin 9 20 46 31 8 114
Epirubicin 6 28 49 26 4 113 0.304
Fever
Doxorubicin 90 11 12 0 2 115
Epirubicin 93 12 8 0 0 113 0.215
Alopecia
Doxorubicin 10 4 15 81 2 112
Epirubicin 15 2 13 80 1 111 0.483
Infection
Doxorubicin 89 14 9 1 2 115
Epirubicin 93 9 6 3 1 112 0.546
Toxicity
The haematological toxicity data are presented in Table 4. They
are expressed either as nadir or as retreatment day (first day ofnext
cycle) values, calculated as the worst reported value over all
cycles. The difference in the lowest leucocyte count on retreatment
day was significant between the doxorubicin and the epirubicin
arm (P = 0.01 1), with a lower value in the former arm. The platelet
nadir (based on 46 patients) was significantly lower in the doxoru-
bicin arm (P = 0.031). Three patients died in the doxorubicin arm
with infectious complications during leucopenia, whereas no toxic
deaths were observed in the epirubicin arm. The data for the non-
haematological toxicities are presented in Table 5, displaying the
maximal toxicity assessed per patient, excluding information after
crossing over.
Mucositis and diarrhoea were significantly lower in the epiru-
bicin-treated patients than in the doxorubicin-treated patients
(P < 0.001 and P = 0.005 respectively). There were also fewer
haemorrhages with epirubicin than with doxorubicin (P = 0.048).
Concerning cardiotoxicity, nine patients in the doxorubicin arm
and two patients in the epirubicin arm experienced clinical conges-
tive heart failure (CHF). However, sporadic measurements of
LVEF precluded detailed assessment ofcardiotoxicity.
DISCUSSION
There is virtually no cure for disseminated breast cancer.
Therefore, treatment of metastatic disease is palliative and aims at
symptom relief and prolongation of life. In this situation, side-
effects oftherapy should be minimal.
The objective of the present study (started in the 1980s) was to
compare the activity and toxicity ofdoxorubicin with its presumed
equally effective but less toxic derivate epirubicin as second-line
chemotherapy in patients with metastatic breast cancer. To the best
of our knowledge, this is the largest randomized trial directly
comparing the two anthracyclines in advanced breast cancer.
Eight smaller randomized studies in metastatic breast cancer
have compared the efficacy of monotherapy, with both drugs
given on an equimolar or equimyelotoxic basis (Table 6). In the
four studies comparing epirubicin with doxorubicin on an
equimolar basis, no differences in response percentages between
the two treatment arms were observed (Brambilla et al, 1986;
Perevodchikova and Valvere, 1987; Lawton et al, 1990; Gasparini
et al, 1991). However, the numbers of patients included in those
studies were small, precluding any firm conclusions. Toxicity,
however, was generally more pronounced in the doxorubicin-
treated patients. The four other studies compared the two drugs on
an expected equimyelotoxic basis with doses ofepirubicin ranging
from 1.4 to 1.5 times the dose of doxorubicin (Jain et al, 1985;
Taguchi et al, 1986; Hortobagyi et al, 1989; Perez et al, 1991).
Similarly none of these studies showed significant differences in
response rates, duration of response or survival between the two
treatment arms.
The efficacy ofequimolar doses ofepirubicin and doxorubicin as
part of a drug combination with fluorouracil and cyclophosphamide
(FEC vs FAC) was investigated in two large randomized trials (The
French Epirubicin Study Group, 1988; The Italian Multicentre Breast
Study with Epirubicin, 1988). Response percentages, duration of
Table 6 Doxorubicin vs epirubicin as single-agent therapy in metastatic breast cancer
Main author Year No. of Dose (mg m-2) Response rates (%)
patients
Doxorubicin Epirubicin Doxorubicin Epirubicin
Brambilla 1986 42 75 75 52 62
Perevodchikova 1987 30 90 90 33 33
Lawton 1990 56 70 70 36 32
Gasparini 1991 43 20a 20a 38 36
Jain 1985 52 60 85 25 25
Taguchi 1986 63 40 60 35 56
Hortobagyi 1989 48 60 90 29 26
Perez 1991 138 60 90 47 49
Bontenbal 1996 233 75 90 36 28
aWeekly administrations.
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response and time to progression did not differ in the two treatment
arms. However, the epirubicin combination showed a lesser degree
ofmyelosuppression, nausea and vomiting.
In our study, no significant differences in response rates were
observed between the two drugs, with 36% compared with 28%
objective responses (CR + PR) for doxorubicin and epirubicin
respectively. However, the study was designed to detect a differ-
ence in response in favour of epirubicin of 20% in 232 patients.
Because the difference in response is smaller, a much larger study
would be needed to detect a possible clinically important differ-
ence in response between both drugs. There was at best a trend in
favour of doxorubicin for the median duration of response (40 vs
30 weeks) and for the median time to progression (23 vs 19
weeks), but the differences were small and duration of survival
was the same in both groups. An explanation for the small differ-
ences we observed in time to progression and duration of response
can possibly be found in the initial design of the study, in that
treatment had to be stopped after a cumulative dose of550 mg m-2
was reached for both drugs. Indeed, 11 patients in the epirubicin
arm who had experienced a response stopped treatment after a
cumulative dose of495-1452 (median 544) mg m-2. Reduction of
the treatment period could have influenced the time to progression
and duration of response, as was found in the studies of Ejlertsen
et al (1993) and Coates et al (1987). On the other hand, dose reduc-
tions occurred more frequently in patients treated with doxoru-
bicin (42% vs 30%).
We observed a statistically significant difference in toxicity in
favour ofepirubicin. Doxorubicin treatment resulted in more bone
marrow depression, mucositis and diarrhoea. In the study of Perez
et al (1991), bone marrow toxicity of doxorubicin 60 mg m-2 and
epirubicin 90 mg m- were almost superimposable, and the same
results were found for gastrointestinal toxicity. Response percent-
ages in this study were indentical, and the authors concluded that
the higher dose of epirubicin had no advantages over the lower
dose of doxorubicin. The increased bone marrow toxicity seen
with doxorubicin gives rise to the question of whether we used an
insufficient dose ofepirubicin.
Bone marrow toxicity is historically used to relate the dose of
one drug to another (Launchbury and Habboubi, 1993). At the
time this study started, clinical experience suggested that doxoru-
bicin 75 mg m-2 and epirubicin 90 mg m- would induce similar
degrees of myelotoxicity (Rozencweig et al, 1984; Bonfante et al,
1982). In 1990, Mouridsen reviewed 10 years of clinical experi-
ence with epirubicin and calculated the equitoxic dose ratio for the
haematological toxicity of doxorubicin and epirubicin to be 1:1.2
(Mouridsen et al, 1990). Drug dosages chosen in this study
fulfilled this criterium. Furthermore, Bastholt et al (1996)
compared the efficacy and toxicity of four different dose levels of
epirubicin in patients with metastatic breast cancer. An increase in
the dose from 90 mg m-2 to 135 mg m-2 resulted in increased toxi-
city but had no impact on the efficacy of the drug. However, the
number of patients in this study was small, and clinically impor-
tant differences between these two doses could not be excluded.
We conclude from this study that a trend that approaches a
significant difference in efficacy is achieved with doxorubicin
75 mg m-' and epirubicin 90 mg m-2 in the treatment of advanced
breast cancer. The equitoxic dose ratio for haematological toxicity
of doxorubicin and epirubicin is > 1: 1.2, whereas the ratio for
cardiotoxicity remains uncertain. On the other hand, using these
dose levels, the treatment with epirubicin is associated with
significantly fewer side-effects.
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